Trial · NCT00297167
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Double-blind Intervention Period | STARTED | Placebo First, Then EUR-1008 (APT-1008) | 17 | |
| First Double-blind Intervention Period | STARTED | EUR-1008 (APT-1008) First, Then Placebo | 16 | |
| First Double-blind Intervention Period | STARTED | EUR-1008 (APT-1008) (Open-label) | 0 | |
| First Double-blind Intervention Period | COMPLETED | Placebo First, Then EUR-1008 (APT-1008) | 17 | |
| First Double-blind Intervention Period | COMPLETED | EUR-1008 (APT-1008) First, Then Placebo | 16 | |
| First Double-blind Intervention Period | COMPLETED | EUR-1008 (APT-1008) (Open-label) | 0 | |
| First Double-blind Intervention Period | NOT COMPLETED | Placebo First, Then EUR-1008 (APT-1008) | 0 | |
| First Double-blind Intervention Period | NOT COMPLETED | EUR-1008 (APT-1008) First, Then Placebo | 0 | |
| First Double-blind Intervention Period | NOT COMPLETED | EUR-1008 (APT-1008) (Open-label) | 0 | |
| Open-label Dose Normalization Period 1 | STARTED | Placebo First, Then EUR-1008 (APT-1008) | 0 | |
| Open-label Dose Normalization Period 1 | STARTED | EUR-1008 (APT-1008) First, Then Placebo | 0 | |
| Open-label Dose Normalization Period 1 | STARTED | EUR-1008 (APT-1008) (Open-label) | 33 | |
| Open-label Dose Normalization Period 1 | COMPLETED | Placebo First, Then EUR-1008 (APT-1008) | 0 | |
| Open-label Dose Normalization Period 1 | COMPLETED | EUR-1008 (APT-1008) First, Then Placebo | 0 | |
| Open-label Dose Normalization Period 1 | COMPLETED | EUR-1008 (APT-1008) (Open-label) | 32 | |
| Open-label Dose Normalization Period 1 | NOT COMPLETED | Placebo First, Then EUR-1008 (APT-1008) | 0 | |
| Open-label Dose Normalization Period 1 | NOT COMPLETED | EUR-1008 (APT-1008) First, Then Placebo | 0 | |
| Open-label Dose Normalization Period 1 | NOT COMPLETED | EUR-1008 (APT-1008) (Open-label) | 1 | |
| Second Double-blind Intervention Period | STARTED | Placebo First, Then EUR-1008 (APT-1008) | 17 | |
| Second Double-blind Intervention Period | STARTED | EUR-1008 (APT-1008) First, Then Placebo | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00297167/flow